Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

infiltrating

infiltrating is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 20
Pipeline programs 6
News articles 0
Drug details — infiltrating
Class
—
Route
—
Patents
20
Programs
6
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

infiltrating is an FDA-listed pharmaceutical active ingredient.

Key facts

INN infiltrating

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Browse pipeline
  1. Autologous Tumor Infiltrating Lymphocytes MDA-TIL Phase 2 · Iovance Biotherapeutics · Malignant Solid Neoplasm
  2. Tumor infiltrating lymphocytes (TIL) LN-145 Phase 2 · Iovance Biotherapeutics · Metastatic Triple Negative Breast Cancer
  3. Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL) Phase 1 · United Therapeutics Europe · Urothelial Carcinoma
  4. Autologous tumor-infiltrating lymphocyte cells Phase 1 · Chinese Academy of · Advanced Solid Tumor
  5. The TILS001 trial Phase 1 · George Institute for · advanced or metastasic triple-negative breast cancer
  6. VHIO20001 Phase 1 · George Institute for · Advanced epithelial tumors and immune checkpoint blockade (I

Related patents

Browse patents

  1. US 12280140

    Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12233075

    Remnant tumor infiltrating lymphocytes and methods of preparing and using the same

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12226434

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12194061

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12188048

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12121541

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12031157

    Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12024718

    Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11998568

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11975028

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11969444

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11939596

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11866688

    Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11865140

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11857573

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11819517

    Methods of using tumor infiltrating lymphocytes in double-refractory melanoma

    Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11667890

    Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion

    Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11541077

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11529372

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11517592

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is infiltrating?

infiltrating is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.